Ads
related to: pfizer patent expirations
Search results
Where Will Pfizer Be in 10 Years?
Motley Fool via Yahoo Finance· 4 months agoPfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the...
Pfizer sees $10 billion-$15 billion in potential revenue from mRNA vaccines by 2030
Reuters via Yahoo News· 1 year agoIn November, Pfizer had raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to...
Here's Why Pfizer Stock Is Looking Increasingly Attractive
Motley Fool· 1 year agoYou might already know the conventional wisdom about Pfizer (NYSE: PFE). The company depends heavily...
Pfizer Is Proving Itself in a Tough Post-Covid Scenario
GuruFocus.com via Yahoo Finance· 2 years agoIn 2021, Pfizer Inc. (NYSE:PFE) succeeded with its coronavirus vaccine, leading to a substantial...
Decoding Pfizer Inc (PFE): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 weeks agoStrengths highlight Pfizer's robust product portfolio and global market presence. Weaknesses underscore the challenges in revenue fluctuations and patent...
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move
Motley Fool via Yahoo Finance· 3 months agoPfizer (NYSE: PFE) has seen its better days. Shares of the big drugmaker have plunged more than 50%...
Why Pfizer Is a Much Better Stock Than You Might Think
Motley Fool via Yahoo Finance· 4 months agoI can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and...
Could Pfizer Stock Help You Retire A Millionaire?
Motley Fool via Yahoo Finance· 4 months agoPfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and...
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
Motley Fool via Yahoo Finance· 1 month agoI owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar...
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Barrons.com· 2 months agoBARRON'S COVER - MAIN Understanding the products from pharmaceutical companies could be the most...